Xilio Therapeutics Grants Inducement Stock Options to New CMO

Xilio Therapeutics granted 105,000 inducement stock options to its newly appointed Chief Medical Officer, Yariv Houvras, at an exercise price of $8.91. Options were also granted to two other new employees.